Home » Stocks » ALIM

Alimera Sciences, Inc. (ALIM)

Stock Price: $7.83 USD -0.17 (-2.13%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 46.16M
Revenue (ttm) 54.39M
Net Income (ttm) -3.86M
Shares Out 5.07M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE 35.84
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $7.83
Previous Close $8.00
Change ($) -0.17
Change (%) -2.13%
Day's Open 8.00
Day's Range 7.48 - 8.27
Day's Volume 37,214
52-Week Range 3.12 - 8.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescri...

GlobeNewsWire - 2 weeks ago

ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...

GlobeNewsWire - 1 month ago

ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterio...

GlobeNewsWire - 1 month ago

ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...

GlobeNewsWire - 2 months ago

ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...

GlobeNewsWire - 2 months ago

ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...

Zacks Investment Research - 2 months ago

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 2 months ago

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 75.51% and 16.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 2 months ago

Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges

GlobeNewsWire - 3 months ago

Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time

GlobeNewsWire - 4 months ago

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for th...

GlobeNewsWire - 4 months ago

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescriptio...

GlobeNewsWire - 4 months ago

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescriptio...

GlobeNewsWire - 4 months ago

ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of pres...

GlobeNewsWire - 4 months ago

ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ILUVIEN receives pricing and reimbursement approvals for b...

GlobeNewsWire - 5 months ago

ATLANTA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...

GlobeNewsWire - 5 months ago

ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...

Zacks Investment Research - 5 months ago

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 5 months ago

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Second Quarter and Recent Company Highlights:

Zacks Investment Research - 6 months ago

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

GlobeNewsWire - 6 months ago

Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time

GlobeNewsWire - 6 months ago

A randomized, controlled , multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care

Seeking Alpha - 8 months ago

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of pres...

Investopedia - 9 months ago

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: CPIX, OSG, RRTS, TTNP
GlobeNewsWire - 9 months ago

ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the manageme...

GlobeNewsWire - 10 months ago

ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology tr...

Seeking Alpha - 10 months ago

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 1 year ago

Company continues to execute on its international expansion strategy

GlobeNewsWire - 1 year ago

ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...

GlobeNewsWire - 1 year ago

ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...

GlobeNewsWire - 1 year ago

ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology tre...

Seeking Alpha - 1 year ago

Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Third Quarter and Recent Company Highlights:

GlobeNewsWire - 1 year ago

ATLANTA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...

GlobeNewsWire - 1 year ago

Consolidated net revenue expected to exceed $12.8 million Consolidated net revenue expected to exceed $12.8 million

GlobeNewsWire - 1 year ago

ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for ...

GlobeNewsWire - 1 year ago

Second country in Europe where patients now have access to this important new treatment option; marketing to commence immediately Second country in Europe where patients now have access to thi...

Seeking Alpha - 1 year ago

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q1 2019 Results - Earnings Call Transcript

About ALIM

Alimera Sciences, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. The company sells its products through direct sales and distributors to physician offices, pharmacies, and hospitals. It has a collaboration ag... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Apr 22, 2010
CEO
C. Daniel Myers
Employees
122
Stock Exchange
NASDAQ
Ticker Symbol
ALIM
Full Company Profile

Financial Performance

In 2019, ALIM's revenue was $53.94 million, an increase of 15.76% compared to the previous year's $46.60 million. Losses were -$10.44 million, -36.25% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 72.41% from the latest price.

Price Target
$13.50
(72.41% upside)
Analyst Consensus: Strong Buy